Human GALT Knockout Cell Line-HeLa
Cat.No. : CSC-RT0716
Host Cell: HeLa Target Gene: GALT
Size: 1x10^6 cells/vial, 1mL Validation: Sequencing
Inquire for Price
Cell Line Information
Cell Culture Information
Safety and Packaging
| Cat. No. | CSC-RT0716 |
| Cell Line Information | A stable cell line with a homozygous knockout of human GALT using CRISPR/Cas9. |
| Target Gene | GALT |
| Host Cell | HeLa |
| Shipping | 10^6 cells/tube |
| Storage | Liquid nitrogen |
| Species | Human |
| Gene ID | 2592 |
| Revival | Rapidly thaw cells in a 37°C water bath. Transfer contents into a tube containing pre-warmed media. Centrifuge cells and seed into a 25 cm2 flask containing pre-warmed media. |
| Media Type | Cells were cultured in DMEM supplemented with 10% fetal bovine serum. |
| Growth Properties | Cells are cultured as a monolayer at 37°C in a humidified atmosphere with 5% CO2. Split at 80-90% confluence, approximately 1:4-1:6. |
| Freeze Medium | Complete medium supplemented with 10% (v/v) DMSO |
| Mycoplasma | Negative |
| Format | One frozen vial containing millions of cells |
| Storage | Liquid nitrogen |
| Safety Considerations |
The following safety precautions should be observed. 1. Use pipette aids to prevent ingestion and keep aerosols down to a minimum. 2. No eating, drinking or smoking while handling the stable line. 3. Wash hands after handling the stable line and before leaving the lab. 4. Decontaminate work surface with disinfectant or 70% ethanol before and after working with stable cells. 5. All waste should be considered hazardous. 6. Dispose of all liquid waste after each experiment and treat with bleach. |
| Ship | Dry ice |
Inquiry
Background
Applications
Galactose-1-phosphate uridyltransferase (GALT) is a key enzyme in the Leloir pathway, responsible for galactose metabolism in organisms. The GALT enzyme itself is a homodimer, with each subunit consisting of approximately 379 amino acids. It facilitates the conversion of galactose-1-phosphate (Gal-1-P) and uridine diphosphoglucose (UDP-glucose) into UDP-galactose and glucose-1-phosphate. The proper function of this enzyme is essential for the efficient utilization and detoxification of galactose from the diet, primarily lactose in milk and dairy products.
Mutations in the GALT gene may result in insufficient or complete absence of enzyme activity, leading to a metabolic disorder known as classic galactosemia. This autosomal recessive disorder can have serious consequences if left untreated, including liver damage, cataracts, intellectual disability, and in severe cases, death. Infants with galactosemia often develop symptoms such as jaundice, vomiting, lethargy, and poor growth soon after drinking milk.
Galactosemia Research: Since the GALT (galactose-1-phosphate uridyltransferase) gene is essential for the normal metabolism of galactose, knocking out this gene in HeLa cells can mimic conditions such as classical galactosemia.
Drug Screening and Therapeutics: The GALT knockout cell line can be used for high-throughput drug screening to identify potential therapeutic compounds that can alleviate or correct the metabolic defects caused by GALT impairment. This is particularly useful for developing treatments for galactosemia and potentially related metabolic diseases.
Functional Genomics: Researchers can study how the loss of GALT affects cellular processes, gene expression, and metabolic networks. This helps understand the role of this gene beyond galactose metabolism and its impact on cell physiology.
Metabolic Flux Analysis: By using the GALT knockout HeLa cell line, scientists can perform flux analysis to track metabolic pathways that are altered due to the lack of a functional GALT.
Synthetic Biology and Metabolic Engineering: The GALT knockout cell line can be used in synthetic biology to engineer cells with customized metabolic pathways. By reintroducing and manipulating GALT in these cells, scientists can create customized metabolic models for a variety of applications, including bioproduction and anabolic circuits.
For research use only. Not intended for any clinical use.
